Multidomain Alzheimers Risk Reduction Study (MARRS) Pilot
多域阿尔茨海默病风险降低研究 (MARRS) 试点
基本信息
- 批准号:9697410
- 负责人:
- 金额:$ 125.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-15 至 2021-11-30
- 项目状态:已结题
- 来源:
- 关键词:Activities of Daily LivingAddressAffectAgeAlzheimer disease preventionAlzheimer&aposs DiseaseAlzheimer&aposs disease related dementiaAlzheimer&aposs disease riskAreaBenefits and RisksCardiovascular DiseasesCognitionCognitiveCohort StudiesCost of IllnessCountryDataDementiaDiabetes MellitusDietDiseaseEducationElderlyEuropeFutureGoalsHealthHealth educationHealthcare SystemsHypertensionImpaired cognitionIncidenceIndividualIntegrated Delivery of Health CareInterventionIntervention StudiesLife StyleMedicalMedication ManagementMental DepressionObesityOutcomeParticipantPatientsPerformancePharmaceutical PreparationsPhysical PerformancePilot ProjectsPopulationPopulation StudyPreparationPrevalencePreventionPrevention trialPrimary PreventionPsyche structurePublic HealthQuality of lifeRandomizedRisk FactorsRisk ManagementRisk ReductionSample SizeSiteSleepSmokingSystemTechnologyTestingWorkbasebehavior changebrain healthcardiovascular risk factorcognitive changecognitive testingdepressive symptomsexperiencegood dietgroup interventionhealth care deliveryhealth care settingshealthy lifestylehigh riskhigh risk populationimprovedinnovationinterestmild cognitive impairmentmodifiable riskmotivated behaviormulti-site trialmultimodalitynovelolder patientpersonalized interventionphase III trialphysical inactivitypilot trialpopulation basedpreventprimary outcomeprogramssecondary outcomesleep qualitysmoking cessationsocialtherapy design
项目摘要
Alzheimer's disease prevalence is expected to triple by 2050, and current medications do not change the
disease course. However, recent studies have projected that up to 30% of Alzheimer's disease may be
preventable by targeting modifiable risk factors. Indeed, population-based studies are finding that, although the
total number of dementia cases is growing, age-specific incidence rates are declining in parallel with
population-level reductions in risk factors such as low education, smoking and cardiovascular disease.
Furthermore, studies in Europe have demonstrated slower cognitive decline and less cognitive impairment with
multi-domain risk reduction interventions. Given the importance of Alzheimer's prevention and the potential
benefits of risk reduction for general as well as brain health, even relatively small reductions in Alzheimer's
incidence would have a dramatic public health impact. Despite the tremendous promise of the multi-domain
risk reduction approach, no primary prevention trials have been performed in the U.S. We propose to conduct
a pilot study of a multi-domain Alzheimer's disease risk reduction intervention in the U.S. To maximize
feasibility and the potential for implementation, we propose to perform our trial within an integrated healthcare
delivery system. In addition, we plan to utilize a personalized intervention, which has proven successful in the
healthcare setting for managing conditions such as depression and hypertension, and which should yield
greatest change on risk factors. Specifically, we propose to randomize 200 higher-risk older adults (age ≥70
with subjective cognitive complaints, performance in the lower end of normal on a cognitive test and ≥ 2
modifiable risk factors that will be targeted by our intervention) to a two year Multi-domain Alzheimer's Risk
Reduction Study (MARRS) intervention or a Health Education (HE) control. In the MARRS intervention group,
the team will work with participants to develop a personalized action plan to address risk reduction including
cardiovascular risk management; smoking cessation; physical, mental and social activity; healthy diet;
improved sleep quality and medication management. The goals of our study are to collect pilot data on the
effect of MARRS on 2-year rate of cognitive decline compared to HE (Aim 1); compare changes in Alzheimer's
modifiable risk factors (Aim 2); and gather preliminary data on the effect of MARRS versus HE on other
important health-related outcomes (Aim 3). We will also compare strategies for identifying higher-risk patients
for this and future studies. This innovative pilot trial will provide critically needed information to support a future
multi-site trial, with the ultimate goal of delaying or preventing cognitive decline leading to Alzheimer's disease.
到2050年,阿尔茨海默病的患病率预计将增加两倍,而目前的药物并不能改变这种趋势
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Eric B Larson其他文献
Neuropathologic Burden and Dementia in Nonagenarians and Centenarians.
九十多岁和百岁老人的神经病理负担和痴呆。
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:9.9
- 作者:
B. Cholerton;Caitlin S. Latimer;Paul K. Crane;M. Corrada;Laura E. Gibbons;Eric B Larson;Claudia H. Kawas;C. D. Keene;T. Montine - 通讯作者:
T. Montine
Dementia prevention, intervention, and care: 2024 report of the emLancet/em standing Commission
痴呆症的预防、干预与照护:《柳叶刀》常设委员会2024年报告
- DOI:
10.1016/s0140-6736(24)01296-0 - 发表时间:
2024-08-10 - 期刊:
- 影响因子:88.500
- 作者:
Gill Livingston;Jonathan Huntley;Kathy Y Liu;Sergi G Costafreda;Geir Selbæk;Suvarna Alladi;David Ames;Sube Banerjee;Alistair Burns;Carol Brayne;Nick C Fox;Cleusa P Ferri;Laura N Gitlin;Robert Howard;Helen C Kales;Mika Kivimäki;Eric B Larson;Noeline Nakasujja;Kenneth Rockwood;Quincy Samus;Naaheed Mukadam - 通讯作者:
Naaheed Mukadam
The epidemiology of Alzheimer’s disease and vascular dementia in Japanese and African-American populations: the search for etiological clues
日本和非裔美国人人群中阿尔茨海默病和血管性痴呆的流行病学:寻找病因线索
- DOI:
- 发表时间:
2000 - 期刊:
- 影响因子:4.2
- 作者:
M. Shadlen;Eric B Larson;Michi Yukawa - 通讯作者:
Michi Yukawa
The eMERGE Network: A consortium of biorepositories linked to electronic medical records data for conducting genomic studies
- DOI:
10.1186/1755-8794-4-13 - 发表时间:
2011-01-26 - 期刊:
- 影响因子:2.000
- 作者:
Catherine A McCarty;Rex L Chisholm;Christopher G Chute;Iftikhar J Kullo;Gail P Jarvik;Eric B Larson;Rongling Li;Daniel R Masys;Marylyn D Ritchie;Dan M Roden;Jeffery P Struewing;Wendy A Wolf - 通讯作者:
Wendy A Wolf
Eric B Larson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Eric B Larson', 18)}}的其他基金
Annual Adult Changes in Thought (ACT) symposium on aging, dementia, and Alzheimer's disease
关于衰老、痴呆和阿尔茨海默病的年度成人思想变化 (ACT) 研讨会
- 批准号:
10066181 - 财政年份:2020
- 资助金额:
$ 125.84万 - 项目类别:
Multidomain Alzheimers Risk Reduction Study (MARRS) Pilot
多域阿尔茨海默病风险降低研究 (MARRS) 试点
- 批准号:
9422490 - 财政年份:2017
- 资助金额:
$ 125.84万 - 项目类别:
The ACT annual symposium: a living, learning, national collaboratory to advance Alzheimer's disease and brain aging research
ACT 年度研讨会:一个活跃、学习、推进阿尔茨海默病和大脑衰老研究的国家合作机构
- 批准号:
9395822 - 财政年份:2017
- 资助金额:
$ 125.84万 - 项目类别:
Development and Use of Network Infrastructure for High-Throughput GWA Studies
高通量 GWA 研究网络基础设施的开发和使用
- 批准号:
7688756 - 财政年份:2007
- 资助金额:
$ 125.84万 - 项目类别:
Development and Use of Network Infrastructure for High-Throughput GWA Studies
高通量 GWA 研究网络基础设施的开发和使用
- 批准号:
7902293 - 财政年份:2007
- 资助金额:
$ 125.84万 - 项目类别:
Development and Use of Network Infrastructure for High-Throughput GWA Studies
高通量 GWA 研究网络基础设施的开发和使用
- 批准号:
7921317 - 财政年份:2007
- 资助金额:
$ 125.84万 - 项目类别:
Development and Use of Network Infrastructure for High-Throughput GWA Studies
高通量 GWA 研究网络基础设施的开发和使用
- 批准号:
7427364 - 财政年份:2007
- 资助金额:
$ 125.84万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 125.84万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 125.84万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 125.84万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 125.84万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 125.84万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 125.84万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 125.84万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 125.84万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 125.84万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 125.84万 - 项目类别:
Research Grant